HomeI9DN • FRA
add
Arbutus Biopharma Corp
Previous close
€2.75
Day range
€2.72 - €2.72
Year range
€2.52 - €4.22
Market cap
589.90M USD
Avg Volume
275.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 1.76M | 15.14% |
Operating expense | 5.83M | 9.79% |
Net income | -24.53M | -37.21% |
Net profit margin | -1.39K | -19.16% |
Earnings per share | -0.18 | -32.01% |
EBITDA | -12.68M | 32.64% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 112.71M | -12.79% |
Total assets | 117.01M | -22.14% |
Total liabilities | 37.85M | 6.17% |
Total equity | 79.16M | — |
Shares outstanding | 191.50M | — |
Price to book | 6.71 | — |
Return on assets | -26.19% | — |
Return on capital | -34.60% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -24.53M | -37.21% |
Cash from operations | -13.39M | 30.60% |
Cash from investing | 11.35M | -2.95% |
Cash from financing | 2.78M | -88.60% |
Net change in cash | 746.00K | -95.56% |
Free cash flow | -3.83M | 69.61% |
About
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Founded
2007
Headquarters
Website
Employees
44
